Search

Your search keyword '"Conca E"' showing total 142 results
Start Over Author "Conca E"
142 results on '"Conca E"'

2. Non-line-of-sight 3D imaging with a single-pixel camera

Author

Musarra, G., Lyons, A., Conca, E., Altmann, Y., Villa, F., Zappa, F., Padgett, M. J., and Faccio, D.

Subjects
Physics - Optics, Electrical Engineering and Systems Science - Image and Video Processing
Abstract

Real time, high resolution 3D reconstruction of scenes hidden from the direct field of view is a challenging field of research with applications in real-life situations related e.g. to surveillance, self-driving cars and rescue missions. Most current techniques recover the 3D structure of a non-lineof-sight (NLOS) static scene by detecting the return signal from the hidden object on a scattering observation area. Here, we demonstrate the full colour retrieval of the 3D shape of a hidden scene by coupling back-projection imaging algorithms with the high-resolution time-of-flight information provided by a single-pixel camera. By using a high effciency Single-Photon Avalanche Diode (SPAD) detector, this technique provides the advantage of imaging with no mechanical scanning parts, with acquisition times down to sub-seconds., Comment: 6 pages, 4 figures

Published
2019
Full Text
View/download PDF

9. SOLUS: Multimodal System Combining Ultrasounds and Diffuse Optics for Tomographic Imaging of Breast Cancer

Author

Taroni, P., primary, Mora, A. Dalla, additional, Di Sieno, L., additional, Maffeis, G., additional, Pifferi, A., additional, Tosi, A., additional, Conca, E., additional, Giudice, A., additional, Ruggeri, A., additional, Tisa, S., additional, Flocke, A., additional, Rosinski, B., additional, Dinten, J.-M., additional, Perriollat, M., additional, Blanquer, G., additional, Fraschini, C., additional, Lavaud, J., additional, Arridge, S., additional, Di Sciacca, G., additional, Farina, A., additional, Gordebeke, P., additional, Venturini, E., additional, and Panizza, P., additional

Published
2022
Full Text
View/download PDF

11. Breast lesion classification based on absorption and composition parameters: a look at SOLUS first outcomes

Author

Fantini, Sergio, Taroni, Paola, Maffeis, G., Pifferi, A., Dalla Mora, A., Di Sieno, L., Cubeddu, R., Tosi, A., Conca, E., Giudice, A., Ruggeri, A., Tisa, S., Flocke, A., Rosinski, B., Dinten, J.-M, Perriollat, M., Fraschini, C., Lavaud, J., Arridge, S., Di Sciacca, G., Farina, A., Panizza, P., Venturini, E., Gordebeke, P., and Taroni, Paola

Published
2023
Full Text
View/download PDF

18. Non-line-of-sight three-dimensional imaging with a single-pixel xamera

Author

Musarra, G., Lyons, A., Conca, E., Altmann, Y., Villa, F., Zappa, F., Padgett, M.J., and Faccio, D.

Subjects
ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION
Abstract

Real-time high-resolution three-dimensional (3D) reconstruction of scenes hidden from the direct field of view is a challenging field of research, with applications in real-life situations related, e.g., to surveillance, self-driving cars, and rescue missions. Most current techniques recover the 3D structure of a non-line-of-sight (NLOS) static scene by detecting the return signal from the hidden object on a scattering observation area. Here, we demonstrate the full color retrieval of the 3D shape of a hidden scene by coupling back-projection imaging algorithms with the high-resolution time-of-flight information provided by a single-pixel camera. By using a high-efficiency single-photon avalanche-diode (SPAD) detector, this technique provides the advantage of imaging with no mechanical scanning parts, with acquisition times down to the subsecond range.

Published
2019

34. Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO

Author

Rossini, D., primary, Cremolini, C., additional, Conca, E., additional, Del Re, M., additional, Busico, A., additional, Pietrantonio, F., additional, Bergamo, F., additional, Danesi, R., additional, Cardellino, G., additional, Tamburini, E., additional, Dell'Aquila, E., additional, Strippoli, A., additional, Masi, G., additional, Tonini, G., additional, Negri, F., additional, Corsi, D., additional, Pella, N., additional, Intini, R., additional, Falcone, A., additional, and Santini, D., additional

Published
2018
Full Text
View/download PDF

39. Initial examples of the SOLUS multimodal potential.

Author

Maffeis, G., Pifferi, A., Dalla Mora, A., Di Sieno, L., Cubeddu, R., Tosi, A., Conca, E., Giudice, A., Ruggeri, A., Tisa, S., Flocke, A., Rosinski, B., Dinten, J.-M., Perriollat, M., Fraschini, C., Lavaud, J., Arridge, S., Di Sciacca, G., Farina, A., and Panizza, P.

Published
2023
Full Text
View/download PDF

40. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP)

Author

Stacchiotti, S., Pantaleo, M.A., Negri, T., Astolfi, A., Tazzari, M., Dagrada, G.P., Urbini, M., Indio, V., Maestro, R., Gronchi, A., Fiore, M., Tos, A.P. Dei, Conca, E., Palassini, E., Vincenzi, B., Grosso, F., Pilotti, S., Castelli, C., Casali, P.G., Stacchiotti, S., Pantaleo, M.A., Negri, T., Astolfi, A., Tazzari, M., Dagrada, G.P., Urbini, M., Indio, V., Maestro, R., Gronchi, A., Fiore, M., Tos, A.P. Dei, Conca, E., Palassini, E., Vincenzi, B., Grosso, F., Pilotti, S., Castelli, C., and Casali, P.G.

Abstract

Item does not contain fulltext, PURPOSE: To report on imatinib mesylate (IM) in patients with metastatic dermatofibrosarcoma protuberans (DFSP)/fibrosarcomatous (FS)-DFSP and on the impact of the treatment on tumor biology. EXPERIMENTAL DESIGN: Ten consecutive patients treated with IM from 2007 to 2015 for a metastatic relapse from DFSP/FS-DFSP were identified. FISH analysis for COL1A1-PDGFB was performed. Two IM-treated and 4 naive FS-DFSP were transcriptionally profiled by RNAseq on HiScanSQ platform. Differential gene expression was analyzed with edgeR (Bioconductor), followed by hierarchical clustering and Principal Component Analysis. Results : All cases featured fibrosarcomatous in the metastasis and retained the COL1A1-PDGFB. Best RECIST response was: 8 partial response, 1 stable disease, and 1 progressive disease. Median progression-free survival was 11 months. Five patients received surgery after IM and all relapsed. IM was restored in 4 patients with a new response. After IM, the most upregulated genes included those encoding for immunoglobulins and those affecting functions and differentiation of endothelial cells. Pathway enrichment analysis revealed upregulation in genes involved in antigen processing and presentation, natural killer-mediated cytotoxicity, and drug and xenobiotics metabolism. Conversely, a significant down-regulation of kinase signaling pathways was detected. CONCLUSIONS: All metastatic cases were fibrosarcomatous. Most patients responded to IM, but PFS was shorter than reported in published series which included both DFSP and FS-DFSP. All patients operated after IM had a relapse, suggesting that IM cannot eradicate metastatic cases and that the role of surgery is limited. Transcriptional profile of naive and posttreatment samples pointed the contribution of immune infiltrates in sustaining the response to IM.

Published
2016

41. Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours

Author

Spagnuolo, R.D., Brich, S., Bozzi, F., Conca, E., Castelli, C., Tazzari, M., Maestro, R., Brenca, M., Gualeni, A.V., Gloghini, A., Stacchiotti, S., Pierotti, M.A., Pilotti, S., Negri, T., Spagnuolo, R.D., Brich, S., Bozzi, F., Conca, E., Castelli, C., Tazzari, M., Maestro, R., Brenca, M., Gualeni, A.V., Gloghini, A., Stacchiotti, S., Pierotti, M.A., Pilotti, S., and Negri, T.

Abstract

Contains fulltext : 171567.pdf (Publisher’s version ) (Open Access), Sunitinib improves the outcomes of patients with solitary fibrous tumours (SFTs). The aim of this study was to investigate and contextualise sunitinib-induced morpho-functional changes in order to gain insights into the drug's mechanism of action.To this end, four surgical specimens obtained from two sunitinib-responsive patients with malignant SFT, and one primary cell culture obtained from fresh tumoral tissue and its stabilised cell line, were studied by means of immunohistochemistry, bright field in situ hybridisation, immunofluorescence/confocal microscopy, and biochemistry.The post-sunitinib surgical samples were characterised by two biologically relevant morpho-functional changes: clear areas and necrotic foci. The first were associated with the attenuation/loss of PDGFRB expression and decreased mTOR signalling, and corresponded to a pathological response. The second were associated with the over-expression of PDGFRB and VEGFA, strong mTOR signalling activation, and the appearance of HIF1alpha expression, hallmarks of pathological progression. The analysis clearly showed that sunitinib reduces the vascular supply network and inhibits tumoral cells. It also either induces autophagy, thus favouring drug response, or impairs autophagy as a result of lysosome sequestration, thus favouring disease progression. These distinct autophagic events were associated with different myeloid immune contextures. Finally, we also found that PDGFRB is one of the components of a complex that includes Beclin 1 and VPS34.The results of these tissue-based analyses provide new insights into sunitinib's mechanism of action in SFT patients.

Published
2016

42. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs)

Author

Negri, T., Bozzi, F., Conca, E., Gronchi, A., Bertulli, R., Fumagalli, E., Pierotti, M.a., Tamborini, E., Pilotti, S., BRICH, SILVIA, Negri, T., Bozzi, F., Conca, E., Brich, Silvia, Gronchi, A., Bertulli, R., Fumagalli, E., Pierotti, M. a., Tamborini, E., and Pilotti, S.

Subjects
Downstream effector, Autocrine-paracrine loop, Downstream effectors, GIST, Histological response ratio, Imatinib, Receptor, Tyrosine kinase
Abstract

As the range of receptor tyrosine kinase (RTK) inhibitors widens, a detailed understanding of the activating mechanisms of KIT/platelet-derived growth factor receptor (PDGFR)A and the related downstream pathways involved in the development and maintenance of GISTs is becoming increasingly important. We analysed areas with different histological response ratios in surgical specimens taken from imatinib-treated and untreated GIST patients in order to investigate KIT and PDGFRA expression/activation, the presence of their cognate ligands and the activation of downstream signalling, by means of biochemistry, immunohistochemistry and flow cytometry. All of the cases showed KIT and PDGFRA co-expression. In addition to the oncogenic activation of mutated receptors, activation of wild-type KIT and wild-type PDGFRA, sustained by heterodimerization and an autocrine-paracrine loop, was demonstrated by the presence of their specific ligands, stem cell factor (SCF) and PDGFA. To confirm RTK activation further, all of the samples (including those with the highest regression ratios) were investigated for downstream effectors, and all proved to have activated downstream signalling. The results show that after the mutated receptors are switched off, heterologous wild-type receptors become important in imatinib-treated GISTs as a means of maintaining signalling activation. Taken together, our findings suggest that drugs targeting wild-type receptors should be tested in imatinib-treated GIST patients.

Published
2009

43. O-007 - Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO

Author

Rossini, D., Cremolini, C., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Bergamo, F., Danesi, R., Cardellino, G., Tamburini, E., Dell'Aquila, E., Strippoli, A., Masi, G., Tonini, G., Negri, F., Corsi, D., Pella, N., Intini, R., Falcone, A., and Santini, D.

Published
2018
Full Text
View/download PDF

47. Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease

Author

Marongiu, R., Ghezzi, D., Ialongo, T., Soleti, F., Elia, A., Cavone, S., Albanese, A., Altavista, M. C., Barone, P., Brusa, L., Cortelli, P., Petrozzi, L., Scaglione, C., Stanzione, P., Tinazzi, M., Zeviani, M., Dallapiccola, B., Bentivoglio, A. R., Valente, E. M., Garavaglia, B., Conca, E., Fasano, A., Marelli, C., Martinelli, P., Nordera, G., Pellecchia, M. T., Marongiu R., Ghezzi D., Ialongo T., Soleti F., Elia A., Cavone S., Albanese A., Altavista M.C., Barone P., Brusa L., Cortelli P., Petrozzi L., Scaglione C., Stanzione P., Tinazzi M., Zeviani M., Dallapiccola B., Bentivoglio A.R., Valente E.M., Garavaglia B., and and the Italian PD Study Group.

Subjects
Proband, Male, Parkinson's disease, Late onset, Protein Serine-Threonine Kinases, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Heterozygote Detection, Gene Frequency, Medicine, Humans, LRRK2, Dardarin, mutation screening, Italy, Mutation frequency, Family history, Allele frequency, Genetics, business.industry, Genetic Carrier Screening, Haplotype, Parkinson Disease, Protein-Serine-Threonine Kinases, Settore MED/26 - NEUROLOGIA, Mutation screening, Amino Acid Substitution, Female, Phenotype, Mutation, Neurology, Mutation (genetic algorithm), Neurology (clinical), business
Abstract

To evaluate the frequency of the LRRK2 G2019S mutation in Italy, we tested 1,072 probands with Parkinson's disease (PD; 822 sporadic and 250 familial): 20 patients (1.9%) carried the G2019S mutation, 11 patients (1.3%) were sporadic, and 9 (4.3%) had a positive family history. Considering only probands with autosomal dominant inheritance, the G2019S frequency raises to 5.2%. All presented a typical phenotype with variable onset and shared the common ancestral haplotype. Mutation frequency raised from 1.2% in early onset PD to 4.0% in late onset PD.

Published
2006

48. Activity of sunitinib in extraskeletal myxoid chondrosarcoma

Author

Stacchiotti, S., primary, Pantaleo, M.A., additional, Astolfi, A., additional, Dagrada, G.P., additional, Negri, T., additional, Dei Tos, A.P., additional, Indio, V., additional, Morosi, C., additional, Gronchi, A., additional, Colombo, C., additional, Conca, E., additional, Toffolatti, L., additional, Tazzari, M., additional, Crippa, F., additional, Maestro, R., additional, Pilotti, S., additional, and Casali, P.G., additional

Published
2014
Full Text
View/download PDF

49. Initial examples of the SOLUS multimodal potential

Author

Contini, Davide, Hoshi, Yoko, O'Sullivan, Thomas D., Maffeis, G., Pifferi, A., Dalla Mora, A., Di Sieno, L., Cubeddu, R., Tosi, A., Conca, E., Giudice, A., Ruggeri, A., Tisa, S., Flocke, A., Rosinski, B., Dinten, J.-M., Perriollat, M., Fraschini, C., Lavaud, J., Arridge, S., Di Sciacca, G., Farina, A., Panizza, P., Venturini, E., Gordebeke, P., and Taroni, P.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results